Search Results

Cutamesine dihydrochloride 5 mg  | 98.83%

TargetMol

Cutamesine dihydrochloride is a selective σ1 receptor agonist (IC50: 17.4 nM). It shows selectivity for σ1 over σ2 receptors, and inhibits angiotensin II-induced cardiomyocyte hypertrophy in vitro and attenuates myocardial hypertrophy in vivo. In a rat model of experimental stroke, it enhances brain plasticity and sensorimotor function.

More Information Supplier Page

Cutamesine dihydrochloride 50 mg  | 98.83%

TargetMol

Cutamesine dihydrochloride is a selective σ1 receptor agonist (IC50: 17.4 nM). It shows selectivity for σ1 over σ2 receptors, and inhibits angiotensin II-induced cardiomyocyte hypertrophy in vitro and attenuates myocardial hypertrophy in vivo. In a rat model of experimental stroke, it enhances brain plasticity and sensorimotor function.

More Information Supplier Page

Cutamesine dihydrochloride 25 mg  | 98.83%

TargetMol

Cutamesine dihydrochloride is a selective σ1 receptor agonist (IC50: 17.4 nM). It shows selectivity for σ1 over σ2 receptors, and inhibits angiotensin II-induced cardiomyocyte hypertrophy in vitro and attenuates myocardial hypertrophy in vivo. In a rat model of experimental stroke, it enhances brain plasticity and sensorimotor function.

More Information Supplier Page

Cutamesine dihydrochloride 10 mg  | 98.83%

TargetMol

Cutamesine dihydrochloride is a selective σ1 receptor agonist (IC50: 17.4 nM). It shows selectivity for σ1 over σ2 receptors, and inhibits angiotensin II-induced cardiomyocyte hypertrophy in vitro and attenuates myocardial hypertrophy in vivo. In a rat model of experimental stroke, it enhances brain plasticity and sensorimotor function.

More Information Supplier Page

Benthiazole 5 mg  | 75.08%

TargetMol

Benthiazole is a broad-spectrum seed protectant that is effective against soil- and seed-borne fungal or bacterial diseases.

More Information Supplier Page

Benthiazole 50 mg  | 75.08%

TargetMol

Benthiazole is a broad-spectrum seed protectant that is effective against soil- and seed-borne fungal or bacterial diseases.

More Information Supplier Page

Cobimetinib 10 mg  | Purity Not Available

TargetMol

Cobimetinib is a selective inhibitor of mitogen-activated protein kinase kinase (MEK) (IC50: 0.9 nM). Cobimetinib specifically binds to and inhibits the catalytic activity of MEK1, resulting in inhibition of extracellular signal-related kinase 2 (ERK2) phosphorylation and activation and decreased tumor cell proliferation.

More Information Supplier Page